Thursday, January 20, 2022

First COVID-19 Vaccine Made by Iran’s Private Sector to Undergo Clinical Trial

More Articles

Avatar of IFP Editorial Staff
IFP Editorial Staffhttps://ifpnews.com/ifp-editorial-staff
The IFP Editorial Staff is composed of dozens of skilled journalists, news-writers, and analysts whose works are edited and published by experienced editors specialized in Iran News. The editor of each IFP Service is responsible for the report published by the Iran Front Page (IFP) news website, and can be contacted through the ways mentioned in the "IFP Editorial Staff" section.
The fifth Iranian-made COVID-19 vaccine has been permitted to undergo the Phase II of its clinical trial.

The recombinant vaccine has been produced by Cinnagen company, and is the first one developed by the private sector.

Four other homegrown vaccines are already undergoing their clinical trials at different phases.

The Covo-Pars vaccine developed by Razi Institute, the conjugate vaccine jointly developed by Iran’s Pasteur Institute and Cuba’s Finlay Institute, the CovIran Barekat vaccine funded by the Executive Office of Imam Khomeini’s Order, and the Fakhra vaccine funded by the Iranian Ministry of Defence are the other four vaccines that are passing their final tests.

Latest article